Med. Pro Praxi 2007; 4(12): 501-505

Ateroskleróza u revmatických onemocnění

MUDr. Šárka Forejtová
Revmatologický ústav, Praha

Chronická zánětlivá revmatická onemocnění jsou provázena zvýšeným výskytem morbidity a mortality z kardiovaskulárních příčin. Onemocnění jsou asociována jednak s výskytem extraartikulárních manifestací jednotlivých revmatických chorob, jednak s vývojem předčasně akcelerované aterosklerózy. Akcelerace vývoje aterosklerózy u revmatiků vzniká důsledkem vlivu jak tradičních rizikových faktorů, tak i podávané medikace, především kortikoidů, a dále působením samotného zánětlivého procesu. Bylo zjištěno, že některé léky podávané za účelem snížení aktivity revmatického onemocnění (metotrexát, anti TNFα) současně snižují výskyt kardiovaskulárních příhod u léčených pacientů. Článek podává přehled o kardiovaskulárním riziku jednotlivých revmatických onemocnění i o vlivu podávané terapie.

Keywords: ateroskleróza, zánětlivá revmatická onemocnění, kardiovaskulární příhoda, anti TNFα

Published: January 16, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Forejtová Š. Ateroskleróza u revmatických onemocnění. Med. praxi. 2007;4(12):501-505.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bacon PA, Stevens RJ, Carruthers DM, Zouny SP, Kotas GD. Accelerated atherosclerosis in autoimmune disease. Autoimmunity reviews 2002; 1: 338-347. Go to original source... Go to PubMed...
    2. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of myocardial infarction (MI) and cerebrovascular accident (CVA) are reduced in patients with rheumatoid arthritis (RA) threated wit anti TNF therapy compared to those threated with traditional DMARDs: result from the BSR Biologic Register. Ann Rheum Dis 2006; 65 (SII): 109.
    3. Doria A, Sherer Y, Neroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin N Am 2005; 31: 355-362. Go to original source... Go to PubMed...
    4. Farsi A, Domeneghetti MP, Brunelli T et al. Actiovation of the immune system and coronary artery disease. Atherosclerosis 2001; 154: 429-436. Go to original source... Go to PubMed...
    5. Gerli R, Bartolini Bocci E, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjögren´s syndrome- role of dyslipidemia. Rheumatology 2006; 45: 1580-1581. Go to original source... Go to PubMed...
    6. Goodson NJ, Wales NJ, Lunt M et al. Mortality in early inflammatory polyartritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010-2019. Go to original source... Go to PubMed...
    7. Goodson NJ, Symmond DP, Scoty DG et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyartritis: a ten-year follow up study of primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-2299. Go to original source... Go to PubMed...
    8. Goodson NJ, Solomon D. The cardiovascular manifestations of rheumatic diseases. Curr Opin Rheum 2006; 18: 135-140. Go to original source... Go to PubMed...
    9. Hansson GH. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 1685-1695. Go to original source... Go to PubMed...
    10. Heeneman S, Daemen M. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007; 19: 358-362. Go to original source... Go to PubMed...
    11. Jacobsson LT, Turesson G, Gulfe A et al. Tratment with tumor necrosis factor blockers is associated with lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218. Go to PubMed...
    12. Jara LJ, Medina G, Vara-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipide syndrome. Clin Rev Allergy Immunol 2003: 25: 79-87. Go to original source... Go to PubMed...
    13. Kimhi O, Caspi D, Bornstein NM, et al. Prevalce and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36: 203-209. Go to original source... Go to PubMed...
    14. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004; 110: 1774-1779. Go to original source... Go to PubMed...
    15. de Leeuw K, Sanders JS, Stegemen C, Smit A, Kallenber CG, Bijl M. Accelerated atheroscelrosis in patients with Wegener´s granulomatosis. Ann Rheum Dis 2005; 64: 753-759. Go to original source... Go to PubMed...
    16. Matucci-Cerinic M, Valentini G, Sorano GG et al. Blood coagulation, fibrinolysis and markers of endotelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 32: 285-292. Go to original source... Go to PubMed...
    17. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-3347. Go to original source... Go to PubMed...
    18. Solomon DH, Carlson EW, Simm EB et al. Cardiovascular morbidity and mortality in women diagnose with rheumatoid arthritis. Circulation 2003; 107: 1303-1307. Go to original source... Go to PubMed...
    19. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: result from a community based study. Ann Rheum Dis 2004; 63: 952-955. Go to original source... Go to PubMed...
    20. Zampieri S, Iaccarino L, Ghirardello A, Tarricone E, Arienti S, Sarzi-Puttini P, Gambari P, Doria A. Systemic lupus erythematosus, atheroasclerosis, and autoantibodies. Ann N Y Acad Sci 2005; 1051: 351-361. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.